GlassScriptPhysician profile
Monique M Gilbert
NPI 1154729606
$3,893.91
in general payments reported to CMS, 2019-2025
28 companies · $644 in 2025
The $644 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $403 · 2022: $807 · 2023: $872 · 2024: $1,168 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,683.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $496.06 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $422.88 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $346.25 | 2021-2025 | |
| Abbvie INC. | $312.94 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.33 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $294.72 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $286.84 | 2021-2025 | Repatha, Evenity, Prolia |
| Phathom Pharmaceuticals, INC. | $229.19 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $189.93 | 2022-2025 | |
| Esperion Therapeutics, INC. | $151.95 | 2021-2025 | Nexletol |
| Pfizer INC. | $149.43 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.78 | 2021-2024 | Xifaxan |
| Abbott Laboratories | $107.14 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Daiichi Sankyo INC. | $90.07 | 2022-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $69.14 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $53.65 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $44.06 | 2021-2023 | |
| Eisai INC. | $32.06 | 2025 | |
| Boston Scientific Corporation | $26.28 | 2025 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $22.77 | 2021 | |
| Medtronic, INC. | $19.75 | 2025 | Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $19.30 | 2022 | |
| Inspire Medical Systems, INC. | $18.41 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $17.57 | 2024 | Xarelto |
| Alvogen INC | $16.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.75 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.14 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.